PDF(Pubmed)
Abstract：
UNASSIGNED: BRAF is a pivotal driver gene in cancer development. Based on this, the combination of dabrafenib and trametinib was approved for treating NSCLC patients with BRAFV600E mutations. However, the majority of BRAF mutations in lung cancer are non-V600E variants, particularly class III mutants, which currently lack targeted therapeutic options and result in unfavorable clinical outcomes.
UNASSIGNED: We present a case of advanced lung adenocarcinoma with a class III BRAFG466V mutation. The patient experienced significant pleural and pericardial effusion, leading to chest tightness and an inability to lie flat. Severe pain and limited mobility from lumbar destruction seriously affected the patient\'s quality of life. Due to the patient\'s intolerance to chemotherapy, dabrafenib and trametinib combination therapy was chosen. After three months of targeted therapy, the patient\'s overall condition significantly improved, enabling self-care, and achieving partial response (PR) as an indicator of treatment efficacy.
UNASSIGNED: The combination therapy of dabrafenib and trametinib demonstrates remarkable clinical benefits for lung adenocarcinoma patients with the BRAFG466V mutation. Targeted therapy should be considered for patients with BRAF class III mutations, especially those in poor general condition and may not tolerate chemotherapy.
UNASSIGNED: We present a case of advanced lung adenocarcinoma with a class III BRAFG466V mutation. The patient experienced significant pleural and pericardial effusion, leading to chest tightness and an inability to lie flat. Severe pain and limited mobility from lumbar destruction seriously affected the patient\'s quality of life. Due to the patient\'s intolerance to chemotherapy, dabrafenib and trametinib combination therapy was chosen. After three months of targeted therapy, the patient\'s overall condition significantly improved, enabling self-care, and achieving partial response (PR) as an indicator of treatment efficacy.
UNASSIGNED: The combination therapy of dabrafenib and trametinib demonstrates remarkable clinical benefits for lung adenocarcinoma patients with the BRAFG466V mutation. Targeted therapy should be considered for patients with BRAF class III mutations, especially those in poor general condition and may not tolerate chemotherapy.
摘要：
■BRAF是癌症发展的关键驱动基因。基于此,达布拉非尼和曲美替尼的组合被批准用于治疗BRAFV600E突变的NSCLC患者.然而,肺癌中的大多数BRAF突变是非V600E变体，尤其是III类突变体，目前缺乏针对性的治疗选择，并导致不利的临床结果。
■我们介绍了1例具有III类BRAFG466V突变的晚期肺腺癌。患者出现明显的胸膜和心包积液，导致胸闷和不能平躺。腰椎破坏引起的剧烈疼痛和活动受限严重影响患者的生活质量。由于病人对化疗不耐受,选择dabrafenib和trametinib联合治疗。经过三个月的靶向治疗,患者的整体状况明显改善，实现自我照顾，并实现部分反应（PR）作为治疗效果的指标。
■达拉非尼和曲美替尼联合治疗对具有BRAFG466V突变的肺腺癌患者具有显著的临床益处。BRAFIII类突变患者应考虑靶向治疗，尤其是那些一般情况较差且可能不耐受化疗的患者。
■我们介绍了1例具有III类BRAFG466V突变的晚期肺腺癌。患者出现明显的胸膜和心包积液，导致胸闷和不能平躺。腰椎破坏引起的剧烈疼痛和活动受限严重影响患者的生活质量。由于病人对化疗不耐受,选择dabrafenib和trametinib联合治疗。经过三个月的靶向治疗,患者的整体状况明显改善，实现自我照顾，并实现部分反应（PR）作为治疗效果的指标。
■达拉非尼和曲美替尼联合治疗对具有BRAFG466V突变的肺腺癌患者具有显著的临床益处。BRAFIII类突变患者应考虑靶向治疗，尤其是那些一般情况较差且可能不耐受化疗的患者。
